NuVasive Specialized Orthopedics Launches Precice Bone Transport in International Markets
September 07 2023 - 7:00AM
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal
solutions company, today announced the commercial launch of
NuVasive Specialized Orthopedics’ (NSO) Precice Bone Transport
system in targeted regions. The latest addition to the less
invasive NSO portfolio is now CE-marked and approved and available
in select markets.
“The NSO difference is our deep commitment to
making complex reconstruction simple and more reproducible,” said
Pete Ligotti, leader of NSO. “The Precice Bone Transport system
addresses a challenging procedure with innovation built for
strength and stability, creating better patient satisfaction and a
simplified surgeon experience.”
Designed for a vast range of bone defects, Precice
Bone Transport is a less invasive solution offering reduced
complexity for the patient and surgeon. The new system, created in
partnership with global, leading limb reconstruction surgeons, has
positively impacted more than 250 trauma and oncology patients.
“Multiple patients of mine have already benefitted
from the all-internal, Precice Bone Transport system,” said Dr.
Thomas Kern, orthopedic traumatologist, BG Klinik Murnau, Germany.
“Being able to utilize the reliable Precice magnetic technology and
treat more patients without the need for external fixation or
amputation, is something I’m proud to be a part of.”
The Precice magnetic adjustable technology utilizes
an external remote to non-invasively lengthen implants. This proven
technology has been implanted by more than 2,000 surgeons 15,000
times in approximately 45 countries.
As part of Globus Medical, NSO is focused on the
design and innovation of disruptive orthopedic solutions for
complex orthopedic reconstruction and limb lengthening.
About Globus Medical, Inc.Globus
Medical is committed to providing innovative technologies and
industry-leading clinical support to help surgeons and healthcare
providers deliver better care around the globe. The Company
provides one of the most comprehensive offerings of musculoskeletal
solutions and enabling technologies to impact the care continuum,
now including the procedurally integrated portfolio of NuVasive.
The Company’s employees are relentlessly focused on advancing
patient care. For more information, please visit
www.globusmedical.com/uniting.
Safe Harbor Statements All
statements included in this press release other than statements of
historical fact are forward-looking statements and may be
identified by their use of words such as “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan” and other similar terms. These
forward-looking statements are based on our current assumptions,
expectations and estimates of future events and trends.
Forward-looking statements are only predictions and are subject to
many risks, uncertainties and other factors that may affect our
businesses and operations and could cause actual results to differ
materially from those predicted. These risks and uncertainties
include, but are not limited to, health epidemics, pandemics
and similar outbreaks, including the COVID-19
pandemic, factors affecting our quarterly results, our ability
to manage our growth, our ability to sustain
our profitability, demand for our products, our ability to
compete successfully (including without limitation our ability to
convince surgeons to use our products and our ability to attract
and retain sales and other personnel), our ability to rapidly
develop and introduce new products, our ability to develop and
execute on successful business strategies, our ability to comply
with laws and regulations that are or may
become applicable to our businesses, our ability to safeguard
our intellectual property, our success in defending legal
proceedings brought against us, trends in the medical device
industry, general economic conditions, and other risks. For a
discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our most recent annual report on Form 10-K
filed with the Securities and Exchange Commission, including the
sections labeled “Risk Factors” and “Cautionary Note Concerning
Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and
other filings with the Securities and Exchange Commission. These
documents are available at www.sec.gov. Moreover, we operate
in an evolving environment. New risk factors and uncertainties
emerge from time to time and it is not possible for us to predict
all risk factors and uncertainties, nor can we assess the impact of
all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statements as
a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Investor contact:Brian
Kearns610-930-1800investors@globusmedical.com
Media contact:Melanie
Ordoñez858-722-3899media@globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2024 to May 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From May 2023 to May 2024